NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Core Insights - Nanobiotix presented initial data from the CONVERGE study, a Phase 2 clinical trial for JNJ-1900 (NBTXR3), at the 2026 European Lung Cancer Conference, focusing on patients with stage 3 inoperable non-small cell lung cancer [1][3] Group 1: Product Overview - JNJ-1900 (NBTXR3) is a novel oncology product utilizing functionalized hafnium oxide nanoparticles, administered via a one-time intratumoral injection and activated by radiotherapy [3] - The mechanism of action is designed to induce significant tumor cell death and trigger an adaptive immune response, potentially applicable to any solid tumor treated with radiotherapy [3][4] Group 2: Clinical Development - The product is being evaluated across multiple solid tumor indications, with a global Phase 3 study (NANORAY-312) focusing on locally advanced head and neck squamous cell cancers [4] - The FDA granted Fast Track designation for JNJ-1900 (NBTXR3) in February 2020 for patients with locally advanced HNSCC not eligible for platinum-based chemotherapy [4] Group 3: Collaboration and Strategy - Nanobiotix has engaged in a collaboration strategy to expand the development of JNJ-1900 (NBTXR3), including a partnership with The University of Texas MD Anderson Cancer Center for several Phase 1 and Phase 2 studies [5] - In 2023, a license agreement was established with Janssen Pharmaceutica NV for the global co-development and commercialization of JNJ-1900 (NBTXR3) [5] Group 4: Study Outcomes - The procedure demonstrated an acceptable safety profile with no serious treatment-emergent adverse events, and initial efficacy responses showed an overall response rate (ORR) of 71.4% and a disease control rate (DCR) of 100% in 7 patients [7]